PURPOSE: To investigate the effect of the Rho-kinase inhibitor, Y27632, on pig corneal endothelial cell (pCEC) culture, and on inflammation and immune regulation of the responses of human cells to pCECs. METHODS: pCECs were cultured with/without Y27632 to assess cell proliferation and in vitro wound healing assay. The level of MCP-1 and VEGF in pCECs stimulated with human TNF-α were measured. Proliferation of human PBMCs stimulated with pCECs, and cytokine production in human T cells, and monocyte migration after stimulation were investigated. RESULTS: Y27632 promoted pCEC proliferation, prevented pCEC death, and enhanced in vitro wound healing. After stimulation, there were significantly lower levels of MCP-1 and VEGF measured in pCECs cultured with Y27632, and significantly reduced human PBMC proliferation, cytokine production, and monocyte migration. CONCLUSIONS: The application of the Rho-kinase inhibitor will be beneficial when culturing pCECs, and may provide a novel therapy to reduce inflammation after corneal xenotransplantation.
PURPOSE: To investigate the effect of the Rho-kinase inhibitor, Y27632, on pig corneal endothelial cell (pCEC) culture, and on inflammation and immune regulation of the responses of human cells to pCECs. METHODS: pCECs were cultured with/without Y27632 to assess cell proliferation and in vitro wound healing assay. The level of MCP-1 and VEGF in pCECs stimulated with human TNF-α were measured. Proliferation of human PBMCs stimulated with pCECs, and cytokine production in human T cells, and monocyte migration after stimulation were investigated. RESULTS:Y27632 promoted pCEC proliferation, prevented pCEC death, and enhanced in vitro wound healing. After stimulation, there were significantly lower levels of MCP-1 and VEGF measured in pCECs cultured with Y27632, and significantly reduced human PBMC proliferation, cytokine production, and monocyte migration. CONCLUSIONS: The application of the Rho-kinase inhibitor will be beneficial when culturing pCECs, and may provide a novel therapy to reduce inflammation after corneal xenotransplantation.
Authors: Fariba Poosti; Saleh Yazdani; M Emmy M Dolman; Robbert Jan Kok; Cheng Chen; Guohua Ding; Marie Lacombe; Jai Prakash; Jacob van den Born; Jan-Luuk Hillebrands; Harry van Goor; Martin H de Borst Journal: Eur J Pharmacol Date: 2012-09-03 Impact factor: 4.432
Authors: S Hippenstiel; S Soeth; B Kellas; O Fuhrmann; J Seybold; M Krüll; C Eichel-Streiber; M Goebeler; S Ludwig; N Suttorp Journal: Blood Date: 2000-05-15 Impact factor: 22.113
Authors: Juan Li; Hidetaka Hara; Yi Wang; Charles Esmon; David K C Cooper; Hayato Iwase Journal: J Inflamm (Lond) Date: 2019-05-28 Impact factor: 4.981
Authors: Tadeu L Montagnoli; Jaqueline S da Silva; Susumu Z Sudo; Aimeé D Santos; Gabriel F Gomide; Mauro P L de Sá; Gisele Zapata-Sudo Journal: Cells Date: 2021-06-30 Impact factor: 7.666